Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies.

[1]  H. Rennert,et al.  Haplo-cord transplant: HLA-matching determines graft dominance , 2017, Leukemia & lymphoma.

[2]  R. Childs,et al.  Haploidentical cord transplantation-The best of both worlds. , 2016, Seminars in hematology.

[3]  R. Larson,et al.  Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  R. Larson,et al.  Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival , 2016, Haematologica.

[5]  I. Buño,et al.  Haplo-cord transplantation using CD34+ cells from a third-party donor to speed engraftment in high-risk patients with hematologic disorders. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  R. Pearse,et al.  A strategy to reduce donor-specific HLA Abs before allogeneic transplantation , 2014, Bone Marrow Transplantation.

[7]  H. Tamaki,et al.  Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT , 2012, Bone Marrow Transplantation.

[8]  P. Terasaki,et al.  Durability of Antibody Removal Following Proteasome Inhibitor-Based Therapy , 2012, Transplantation.

[9]  J. Ritz,et al.  Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. , 2011, Blood.

[10]  R. Larson,et al.  Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. , 2011, Blood.

[11]  P. Thall,et al.  Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. , 2011, Blood.

[12]  H. Azuma,et al.  The impact of anti-HLA antibodies on unrelated cord blood transplantations. , 2010, Blood.

[13]  P. Terasaki,et al.  Abrogation of Anti-HLA Antibodies via Proteasome Inhibition , 2009, Transplantation.

[14]  M. Stegall,et al.  Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody Production , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  J. Klein,et al.  The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. , 2007, Blood.

[16]  J. Hows,et al.  Incidence and specificity of HLA antibodies in multitransfused patients with acquired aplastic anemia , 2004, Transfusion.

[17]  R. Hansen,et al.  Intravenous Immunoglobulin Mediates an Increase in Anti-Platelet Antibody Clearance via the FcRn Receptor , 2002, Thrombosis and Haemostasis.

[18]  W. Stock,et al.  Stem cell transplantation eliminates alloantibody in a highly sensitized patient. , 2001, Transplantation.

[19]  A. Ballestrero,et al.  Proteasome inhibitors: antitumor effects and beyond , 2007, Leukemia.

[20]  Schroeder Jo,et al.  Antibody rebound after plasmapheresis: experimental evidence and clinical consequences. , 1990 .

[21]  H. Euler,et al.  Antibody rebound after plasmapheresis: experimental evidence and clinical consequences. , 1990, Progress in clinical and biological research.